CRIS Current Research Information System

ZAMAGNI, ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.709
AS - Asia 9.048
EU - Europa 6.785
SA - Sud America 595
AF - Africa 557
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 4
Totale 26.712
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.593
CN - Cina 2.939
SG - Singapore 2.698
IT - Italia 1.635
VN - Vietnam 1.559
GB - Regno Unito 1.441
DE - Germania 850
SE - Svezia 765
HK - Hong Kong 651
IN - India 443
BR - Brasile 430
KR - Corea 394
RU - Federazione Russa 364
NL - Olanda 333
FR - Francia 291
IE - Irlanda 257
UA - Ucraina 217
CI - Costa d'Avorio 187
FI - Finlandia 134
JP - Giappone 121
ZA - Sudafrica 120
TG - Togo 101
EE - Estonia 100
SC - Seychelles 98
AR - Argentina 77
AT - Austria 69
BG - Bulgaria 67
CH - Svizzera 60
CA - Canada 58
ID - Indonesia 48
BE - Belgio 46
JO - Giordania 40
MX - Messico 40
ES - Italia 39
PL - Polonia 38
EC - Ecuador 27
BD - Bangladesh 24
IR - Iran 22
NG - Nigeria 20
TR - Turchia 19
CO - Colombia 16
CZ - Repubblica Ceca 15
GR - Grecia 14
CL - Cile 13
IL - Israele 12
LB - Libano 12
AU - Australia 10
IQ - Iraq 10
PH - Filippine 9
UY - Uruguay 9
LT - Lituania 8
MA - Marocco 8
PY - Paraguay 8
RO - Romania 8
EG - Egitto 6
PE - Perù 6
RS - Serbia 6
SA - Arabia Saudita 6
UZ - Uzbekistan 6
AL - Albania 5
KZ - Kazakistan 5
VE - Venezuela 5
DO - Repubblica Dominicana 4
HR - Croazia 4
MY - Malesia 4
PK - Pakistan 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
BZ - Belize 3
HN - Honduras 3
PT - Portogallo 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
CY - Cipro 2
GH - Ghana 2
GT - Guatemala 2
KE - Kenya 2
KG - Kirghizistan 2
LV - Lettonia 2
MK - Macedonia 2
MN - Mongolia 2
NC - Nuova Caledonia 2
NO - Norvegia 2
NP - Nepal 2
NZ - Nuova Zelanda 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
TW - Taiwan 2
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BY - Bielorussia 1
CD - Congo 1
CG - Congo 1
CR - Costa Rica 1
DZ - Algeria 1
ET - Etiopia 1
EU - Europa 1
Totale 26.692
Salva come PNG Salva come JPEG
Città #
Singapore 1.802
Southend 1.229
Ashburn 1.164
Fairfield 1.030
Hefei 902
Chandler 841
Hong Kong 648
Woodbridge 483
Seattle 446
Wilmington 410
Houston 403
Seoul 391
Bologna 385
Dallas 377
Beijing 366
Cambridge 351
Ann Arbor 345
Ho Chi Minh City 331
Princeton 310
Dong Ket 286
Santa Clara 271
Hanoi 254
Dublin 253
Boardman 246
Abidjan 187
Los Angeles 155
Milan 143
New York 127
Nanjing 119
Jacksonville 117
Westminster 113
Tokyo 108
Padova 103
Berlin 101
Lomé 101
Helsinki 87
Bengaluru 82
Bremen 81
Buffalo 78
Munich 78
Jinan 74
San Diego 68
Sofia 67
Frankfurt am Main 64
Redondo Beach 64
Turin 64
Shenyang 61
Saint Petersburg 60
Hyderabad 55
Redwood City 51
Changsha 49
Guangzhou 46
Redmond 44
Shanghai 44
Tianjin 44
Brussels 43
Rome 43
Florence 42
Haiphong 42
São Paulo 42
Amman 40
Nuremberg 40
Bern 39
Nanchang 39
Vienna 37
Zhengzhou 37
Jakarta 34
Amsterdam 33
Falls Church 33
Chicago 32
Hebei 32
Falkenstein 30
Lappeenranta 30
London 30
Fabriano 27
Medford 27
Hangzhou 26
Salsomaggiore Terme 26
Jiaxing 25
Paris 24
Shenzhen 24
Tongling 24
Warsaw 24
Des Moines 23
Dongguan 23
Mülheim 23
Washington 23
Council Bluffs 22
Phoenix 22
Brooklyn 21
Norwalk 21
Toronto 21
Wuhan 21
Olalla 20
Ha Long 19
Da Nang 18
Pune 18
Abeokuta 17
Dearborn 17
Fuzhou 17
Totale 17.430
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 664
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 284
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. 283
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 236
BoBafit: A copy number clustering tool designed to refit and recalibrate the baseline region of tumors’ profiles 234
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 231
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 230
Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma. 229
A NEW RISK STRATIFICATION STRATEGY IN NEWLY DIAGNOSED MULTIPLE MYELOMA: AN ANALYSIS ON MATURE DATA FROM EUROPEAN CLINICAL TRIALS WITHIN THE HARMONY BIG DATA PLATFORM 208
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes 206
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. 206
A new risk stratification model (R2-ISS) in Newly Diagnosed Multiple Myeloma: Analysis of Mature Data from 7077 patients collected by European Myeloma Network Within HARMONY Big Data Platform 202
Assessmen of disease ativity in multiple myeloma with FDG-PET imaging 201
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 199
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. 196
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 194
The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma. 189
A Comparison of Different Staging Systems for Multiple Myeloma: Can the MRI Pattern Play a Prognostic Role? 188
11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. 185
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. 183
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma 183
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. 181
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma 181
Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation. 179
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 179
Use of FDG-PET imaging for assessment of disease activity in patients with multiple myeloma 178
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. 178
Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma 177
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. 175
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 175
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 173
Contrast enhanced MRI and (18)F-FDG PET-CT in the assessment of multiple myeloma: a comparison of results in different phases of the disease 173
Thalidomide maintenance in multiple myeloma: certainties and controversies. 171
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 171
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 171
Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients 169
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. 168
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 168
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 168
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study 166
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. 165
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation 165
Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. 164
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. 162
Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study 160
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. 160
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 159
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 159
Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy 158
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. 156
Dermoscopy of cutaneous involvement by multiple myeloma 155
Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. 154
Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe) 153
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients 152
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 152
Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe) 151
Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma 150
The role of imaging techniques in the management of multiple myeloma 150
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents 150
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. 150
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 150
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 150
Early use of PEPA dialyzer for light chains removal and for the recovery from myeloma cast nephropathy: A case report 150
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 149
Genomic characterization of the putative myeloma stem cells clone reveals alterations possibly correlated with the origin of disease. 148
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 148
Inverse probability weighting to estimate causal effect of a singular phase in a multiphase randomized clinical trial for multiple myeloma 147
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. 146
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 146
Oxytocin Modulates Osteogenic Commitment in Human Adipose-Derived Stem Cells 143
Comparison between 18F-FDG PET/CT and 11C-Choline PET/CT for the evaluation of multiple myeloma 143
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation 143
IMWG consensus on risk stratification in multiple myeloma. 143
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma 141
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. 141
Role of (18)F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. 140
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. 140
18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone. 140
Diagnosis, treatment, and response assessment in solitary plasmacytoma: Updated recommendations from a European Expert Panel 140
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma 138
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treatedwith zoledronic acid and thalidomide-dexamethasone. 138
Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials 137
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. 135
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. 134
Maintenance therapy in newly diagnosed multiple myeloma: current recommendations. 134
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 133
From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives 133
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 133
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 131
A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol 131
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 130
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group 130
Oxytocin modulates osteogenic commitment in human adipose-derived mesenchymal stem cells 129
Bones in Multiple Myeloma: Imaging and Therapy 129
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 128
European Myeloma Network Group review and consensus statement on primary plasma cell leukemia 128
Autologous transplantation and maintenance therapy in multiple myeloma. 128
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing 127
Role of consolidation therapy in transplant eligible multiple myeloma patients. 127
Report of the 6th International Workshop on PET in lymphoma 126
Totale 16.864
Salva come PNG Salva come JPEG
Categoria #
all - tutte 79.871
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 79.871
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.503 0 0 0 0 0 81 55 137 254 154 139 683
2021/20222.916 250 124 186 206 274 142 82 220 139 242 550 501
2022/20233.506 352 533 161 514 230 285 112 194 554 135 265 171
2023/20241.323 83 182 97 100 116 264 77 127 34 93 84 66
2024/20255.039 209 568 422 411 522 266 429 170 135 505 403 999
2025/20267.526 1.253 1.886 1.358 1.062 1.323 644 0 0 0 0 0 0
Totale 27.331